https://www.selleckchem.com/pr....oducts/stat-in-1.htm
Comparable changes in LVEF (fulacimstat 3.5% ± 5.4%, placebo 4.0% ± 5.0%, P = .69), LVEDVI (fulacimstat 7.3 ± 13.3 mL/m2, placebo 5.1 ± 18.9 mL/m2, P = .54), and LVESVI (fulacimstat 2.3 ± 11.2 mL/m2, placebo 0.6 ± 14.8 mL/m2, P = .56) were observed in both treatment arms. CONCLUSION Fulacimstat was safe and well tolerated in patients with left-ventricular dysfunction (LVD) after first STEMI but had no effect on cardiac remodeling. BACKGROUND An amassing body of evidence exists to support an association between the use of immune checkp
Like
Comment
Share
